Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

101.90
CHF
+49.04
(+92.78%)
3.36EPS
Feb 23Next Earn
Halozyme Therapeutics, Inc.
BX:RV7
(BX Swiss)

Recent

price

101.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.15
0.55
0.38
0.49
0.62
1.07
1.15
2.33
1.06
1.36
1.97
3.17
4.85
6.31
8.04
11.71
15.51
Revenue per Share
-0.57
-0.19
-0.48
-0.74
-0.56
-0.26
-0.81
0.46
-0.56
-0.5
0.95
2.88
1.48
2.14
3.52
2.66
4.18
Basic EPS, GAAP
-0.49
-0.34
-0.59
-0.46
-0.4
-0.31
-0.42
0.98
-0.38
-0.62
0.39
2.13
1.73
2.84
3.71
2.99
7.62
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.2
0.11
0.44
-0.18
0.33
0.34
-0.25
1.47
1.73
0.67
1.12
1.44
1.26
0.66
2.97
0.42
-0.49
Book Value per Share
0.2
0.11
0.44
-0.18
0.33
0.34
-0.25
1.47
1.73
0.67
1.12
1.44
-5.84
-6.39
-3.71
-12.9
-13.49
Tangible Book Value per Share
94
102
111
112
122
126
127
136
143
144
136
140
136
131
126
119
116
Basic Weighted Avg Shares
14
56
42
55
75
135
147
317
152
196
268
443
660
829
1,015
1,397
1,802
Sales/Revenue/Turnover
-398.25
-35.37
-126.7
-146.78
-83.68
-20.33
-56.72
25.58
-45.65
-34.5
53.91
62.24
40.53
40.71
54.32
57.47
55.91
Operating Margin (%)
2
1
1
1
2
2
2
2
2
4
3
3
50
85
81
88
129
Depreciation Expense
-53
-20
-54
-83
-68
-32
-103
63
-80
-72
129
403
202
282
444
317
485
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.17
- -
18.8
19.16
20.29
32.13
25.89
Effective Tax Rate (%)
-390.79
-35.25
-126.53
-152.34
-90.76
-23.86
-70.23
19.89
-52.9
-36.86
48.24
90.84
30.62
33.96
43.74
22.69
26.93
Profit Margin (%)
74
47
112
70
137
109
202
379
278
458
133
809
608
634
946
648
1,371
Working Capital
- -
- -
31
50
50
28
199
125
35
383
- -
787
1,493
1,499
1,506
2,143
2,945
LT Debt
20
11
49
-20
41
43
-32
208
249
92
151
197
170
84
364
49
-55
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
27.67
- -
15.82
16.79
25.51
15.68
19.18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
28.66
- -
15.7
18.21
26.56
16.21
19.26
Return on Capital (%)
-390.69
-126.52
-179.24
- -
- -
-76.42
- -
- -
-35.14
-42.41
106.33
231.44
110.23
222.07
198.42
153.59
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
209
209
306
LT Borrowings
1,936
1,938
2,945
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
118
114
113
Market Capitalization
8,054
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,003
933
1,847
Cash, Cash Equivalents & STI
319
231
1,074
Accounts Receivable, Net
468
462
530
Inventories
155
137
133
Total Current Liabilities
363
344
476
Payables & Accruals
154
135
170
ST Debt
209
209
306
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-68.26%
42.7%
-86.58%
Free Cash Flow
-4.51%
100.4%
-23.82%
Net Income, GAAP
-22.73%
46.11%
-28.64%
Sales/Revenue/Turnover
33.82%
40.04%
37.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
196
231
290
298
1,015
2025
265
326
354
452
1,397
2026
377
481
493
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.61
0.74
1.08
1.09
3.52
2025
0.96
1.37
1.5
-1.21
2.66
2026
1.28
1.97
2.18
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.

Company News

  • Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?

  • Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

  • Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

  • NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump

  • Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

  • Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

  • HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

  • Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

  • U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

  • What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

  • Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics

  • Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates

  • HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

  • Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

  • HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

  • These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  • Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

  • HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order

  • Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?

  • 11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management